Sacituzumab tirumotecan for previously treated thymic carcinoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new drug called sacituzumab tirumotecan for thymic carcinoma that has spread or come back after prior treatment. The goal is to see if this drug can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of thymic carcinoma that has spread, is not removable by surgery, or has come back after surgery.
- You must have already had chemotherapy that included a platinum drug (like cisplatin or carboplatin).
- You must be 18 or older and able to care for yourself (fully active or limited in heavy physical work only).
- You cannot have symptomatic brain metastases or spinal metastases needing radiation or surgery.
- You must not have fluid buildup around the heart, lungs, or belly that needs treatment.
- Your blood counts and organ function (kidneys, liver) must be within certain limits, and you must have adequate oxygen levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called sacituzumab tirumotecan for people with recurrent or metastatic adenoid cystic carcinoma or papillary thyroid carcinoma. The drug works by targeting a protein on cancer cells to deliver treatment directly, which may help shrink tumors or slow their growth.
This trial tests a new drug, sacituzumab tirumotecan, in people with advanced thymic carcinoma that has spread or cannot be removed with surgery. It is for those whose cancer has gotten worse after at least one round of platinum-based chemotherapy.
This study tests a new drug called sacituzumab tirumotecan for people with advanced thymus tumors that have already been treated once. The drug is given as an infusion and may help control the tumor.
This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with early-stage, high-risk breast cancer that hasn't spread. The drug is given before surgery to see if it can shrink tumors and improve outcomes.
This trial tests a new drug called sacituzumab tirumotecan (also known as MK-2870) for people with advanced small bowel cancer that has stopped responding to standard platinum-based chemotherapy. The drug is designed to target a protein called TROP2 on cancer cells and deliver a chemo-like payload directly to them, which may help shrink or control the tumor.
This trial tests a new medication, sacituzumab tirumotecan, for people with anal or rectal cancer that has spread or cannot be removed and has not responded to previous treatments. The drug is designed to target and kill cancer cells.
Hear when a new Unresectable Thymic Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.